临床瘤学中的竞争风险数据
1Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, United States.
Frontiers in oncology
|April 19, 2024
概括
对抗风险数据分析对于癌症治疗评估至关重要,但往往被忽视. 这项研究提高了认识,并为在癌症临床研究中分析竞争风险提供了准确结果的指导.
科学领域:
- 在瘤学瘤学.
- 生物统计学 生物统计学
- 临床试验 临床试验
背景情况:
- 竞争性风险数据在癌症研究中很常见,但往往没有被识别或分析.
- 不准确的分析导致治疗疗效的不完整和不正确的呈现.
- 这可能导致对研究结果的不正确解释.
研究的目的:
- 在癌症研究中提高对竞争风险数据的认识.
- 提供对竞争风险数据的总体概述.
- 为癌症临床研究中进行竞争性风险数据分析提供指导.
主要方法:
- 审查关于竞争风险分析的现有文献.
- 来自癌症临床研究的说明性例子.
- 关于竞争性风险的统计方法的指导.
主要成果:
- 竞争性风险分析对于准确评估癌症治疗效用至关重要.
- 确定了处理竞争风险数据的常见陷.
- 标准化方法可以改善对临床试验结果的解释.
结论:
- 提高对竞争风险的认识和应用数据分析对于癌症研究至关重要.
- 适当的分析确保准确报告治疗疗效和临床效用.
- 本指南旨在提高癌症研究的严谨性和影响.
相关概念视频
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Hazard Ratio
116
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
116
Comparing the Survival Analysis of Two or More Groups
179
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
179
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K


